Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 73.65% is in line with its 5-year average of 74.12%, around the middle of its 5-year range (67.53%–79.28%).
0.46% above its 12-month average of 73.31%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 74.27%.
GROSS MARGIN
73.65%
GROSS MARGIN AVG TTM
73.31%
GROSS MARGIN AVG 3Y
73.88%
GROSS MARGIN AVG 5Y
74.12%
GROSS MARGIN AVG 10Y
74.52%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.46%
CURRENT VS 3Y AVG
-0.32%
CURRENT VS 5Y AVG
-0.63%
CURRENT VS 10Y AVG
-1.17%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
42.91%
median of 600 covered companies
CURRENT VS SECTOR MEDIAN
+71.64%
vs the sector median at left
OrthoPediatrics Corp.
Market Cap
$580.22M
Gross Margin
73.65%
TTM Avg
73.31%
3Y Avg
73.88%
5Y Avg
74.12%
Market Cap
$569.15M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$563.97M
Gross Margin
67.04%
TTM Avg
65.22%
3Y Avg
62.15%
5Y Avg
65.14%
Market Cap
$596.72M
Gross Margin
99.76%
TTM Avg
98.92%
3Y Avg
99.03%
5Y Avg
96.38%
Market Cap
$605.22M
Gross Margin
35.58%
TTM Avg
39.19%
3Y Avg
43.45%
5Y Avg
55.13%
Market Cap
$552.54M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$551.88M
Gross Margin
98.63%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
100.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| OrthoPediatrics Corp. (KIDS) | $580.22M | 73.65% | 73.31% | 73.88% | 74.12% |
| ArriVent BioPharma, Inc. (AVBP)vs › | $569.15M | 0.00% | 0.00% | 0.00% | 0.00% |
| Aquestive Therapeutics, Inc. (AQST)vs › | $563.97M | 67.04% | 65.22% | 62.15% | 65.14% |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $596.72M | 99.76% | 98.92% | 99.03% | 96.38% |
| CorMedix Inc. (CRMD)vs › | $562.50M | 82.78% | 90.56% | 68.85% | 51.96% |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| Fulgent Genetics, Inc. (FLGT)vs › | $605.22M | 35.58% | 39.19% | 43.45% | 55.13% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $552.54M | 0.00% | 0.00% | 0.00% | 0.00% |
| CytomX Therapeutics, Inc. (CTMX)vs › | $551.88M | 98.63% | 100.00% | 100.00% | 100.00% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $549.58M | 73.28% | 79.19% | 65.08% | 51.90% |
Gross Margin
73.7%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 74.27% |
| 2026-03-31 | 73.09% |
| 2025-12-31 | 73.22% |
| 2025-09-30 | 73.92% |
| 2025-06-30 | 72.07% |
| 2025-03-31 | 73.00% |
| 2024-12-31 | 67.53% |
| 2024-09-30 | 73.41% |
| 2024-06-30 | 77.27% |
| 2024-03-31 | 72.00% |
| 2023-12-31 | 71.02% |
| 2023-09-30 | 77.44% |
| 2023-06-30 | 75.90% |
| 2023-03-31 | 74.59% |
| 2022-12-31 | 68.48% |
| 2022-09-30 | 74.07% |
| 2022-06-30 | 75.87% |
| 2022-03-31 | 79.28% |
| 2021-12-31 | 72.87% |
| 2021-09-30 | 73.98% |
| 2021-06-30 | 76.58% |
| 2021-03-31 | 76.06% |
| 2020-12-31 | 79.89% |
| 2020-09-30 | 79.44% |
| 2020-06-30 | 74.02% |
| 2020-03-31 | 74.67% |
| 2019-12-31 | 76.25% |
| 2019-09-30 | 76.62% |
| 2019-06-30 | 74.83% |
| 2019-03-31 | 72.70% |
| 2018-12-31 | 72.17% |
| 2018-09-30 | 75.71% |
| 2018-06-30 | 74.75% |
| 2018-03-31 | 73.75% |
| 2017-12-31 | 75.61% |
| 2017-09-30 | 76.69% |
| 2017-06-30 | 73.82% |
| 2017-03-31 | 75.96% |
| 2016-12-31 | 67.95% |
| 2016-09-30 | 70.62% |
| 2016-06-30 | 70.56% |
| 2016-03-31 | 74.14% |
| 2015-03-31 | 71.42% |
